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Background: The understanding of gender differences in inflammatory bowel disease (IBD) patients 
is an important step towards tailored treatment for the individual patient. The aim of this study was 
to compare disease phenotype, clinical manifestations, disease activity, and healthcare utilization 
between men and women with Crohn’s disease (CD) and ulcerative colitis (UC).
Methods: Two multicenter observational cohort studies with a prospective design were used 
to explore the differences between men and women regarding demographic and phenotypic 
characteristics and healthcare utilization. Detailed data on IBD-phenotype was mainly available 
from the Dutch IBD Biobank, while the COIN cohort provided healthcare utilization data.
Results: In the Dutch IBD Biobank study, 2118 CD patients and 1269 UC patients were analysed. 
Female CD patients were more often current smokers, and male UC patients were more often 
previous smokers. Early onset CD (< 16 years) was more frequently encountered in males than 
in females (20% versus 12%, P < 0.01). Male CD patients were more often diagnosed with ileal 
disease (28% versus 20%, P < 0.01) and underwent more often small bowel and ileocaecal resection. 
Extraintestinal manifestations (EIMs) were more often encountered in female IBD patients. In 
the COIN study, 1139 CD patients and 1213 UC patients were analysed. Male CD patients used 
prednisone more often and suffered more often from osteopenia. IBD-specific healthcare costs 
did not differ between male and female IBD patients.
Conclusions: Sex differences in patients with IBD include age of onset, disease location, and EIM 
prevalence. No large differences in therapeutic management of IBD were observed between men 
and women with IBD.
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Introduction
Inflammatory bowel diseases (IBD), such as Crohn’s disease (CD) and ulcerative colitis (UC), are 
immune-mediated chronic inflammatory diseases of the gastrointestinal tract. More than 1 million 
residents from the United States of America and 2.5 million Europeans are estimated to suffer 
from IBD.1
Treatment strategies for IBD are aimed at inducing and maintaining long-term remission.2,3 In 
other chronic conditions, such as ischemic heart disease, it is recognized that the treatment of 
men and women requires a different approach.4 Although incidence rates for male and female 
IBD patients are well established (approximately 1:1.5 in CD and 1:1.2 in UC, respectively), data 
on sex-specific differences with respect to disease characteristics of IBD are limited.5-7 Female sex 
has been reported as a risk factor for extraintestinal manifestations (EIMs).5 Studies focusing on 
predictors for postoperative recurrence of IBD have incorporated sex as a potential predictor, but 
these studies report conflicting outcomes regarding sex.8-10 Data regarding differences in healthcare 
consumption between male and female IBD patients are very limited. One study that compared the 
use of treatment modalities between hospitalized female and male adolescent CD patients did not 
observe any significant difference regarding medical procedures, such as endoscopies and blood 
transfusions.11 Also in pediatric IBD patients, no differences have been found between males and 
females regarding the risk for first gastrointestinal surgery.11-13 The understanding of differences in 
disease characteristics and current clinical approach between female and male IBD patients is an 
important step toward tailored treatment in the individual patient.14,15
In this study, we aim to compare the phenotype, clinical manifestations, disease course, 
medical treatment, and other consumption of the healthcare system between adult male and 
female IBD patients, using 2 large independent multicenter observational cohorts.
Methods
Dutch IBD Biobank
The Dutch IBD Biobank is part of the Parelsnoer Institute16 and was founded in 2007 with the 
aim to facilitate basic science and clinical research by providing high-quality biomaterials and an 
extensive patient data collection. Every adult patient diagnosed with IBD and treated in one of the 
8 university medical centers (UMCs) in the Netherlands is eligible for inclusion. Data are collected 
prospectively by using a standardized information model containing 225 IBD-related items. For the 
present study, demographic items, diagnosis, smoking status, disease location, disease behaviour, 
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surgery-related items, medication use, EIMs, and disease complications were used. Definitions of 
these items can be found in Supplementary Methods Table 1.
COIN study
The COIN study (costs of inflammatory bowel disease in the Netherlands) is a prospective multicenter 
study initiated in 2010, designed to assess costs and health-related quality of life (HrQoL).17 CD and 
UC patients who were 18 years or older and attending the IBD units from 7 university medical 
centers (UMCs) and 7 general hospitals were eligible for participation. The study design has 
previously been described in detail.17 In short, data were collected through a web-based baseline 
questionnaire, followed by quarterly questionnaires. For this study, data regarding demographics, 
smoking status, disease course and EIMs were collected at baseline. And IBD-specific healthcare 
consumption (medication use, use of diagnostics, outpatient clinic visits, hospital admissions, and 
surgical procedures) was measured after 3 months of follow-up. Healthcare costs were calculated 
by multiplying units of self-reported healthcare utilization during follow-up by their corresponding 
unit prices.18 Total healthcare costs consisted of medication use, hospital admissions, surgeries, 
diagnostic procedures, and outpatient clinic visits. Costs were expressed in Euros for the year 
2015. Definitions of all above-mentioned items can be found in Supplementary Methods Table 2.
Analysing the Dutch IBD Biobank and COIN cohort
To prevent duplicates, only patients in the COIN cohort that did not participate in the Dutch IBD 
Biobank cohort were included in the analysis. The 2 cohorts have a different study aim. The Dutch 
IBD Biobank was founded to facilitate basic science and clinical research by providing high-quality 
biomaterials and an extensive patient data collection. The Dutch IBD Biobank is rigorous and 
detailed in phenotype collection (225 IBD items). The COIN study was designed to assess costs and 
health-related quality of life (HrQoL). Furthermore, the cohorts differ regarding patient inclusion, 
data collection, and selection of patients. In the Dutch IBD Biobank, patients were included and 
followed during hospital visits for IBD. Data in the COIN were collected through a web-based 
baseline questionnaire, followed by quarterly questionnaires. Patients were invited to participate 
at home. The Dutch IBD Biobank consisted entirely of IBD patients treated in tertiary referral centers 
(i.e., university hospitals). Patients were included during a hospital visit for IBD. Data collection is 
based on electronic patient databases. Patients of the COIN study were self-reported through 
questionnaires and recruited from university hospitals and general hospitals. Because of the distinct 
features in each of the cohorts, analyses of the Dutch IBD Biobank study and the COIN study were 
performed separately.
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Statistical analysis
In all analyses, IBD-unclassified (IBD-U) and IBD-indeterminate (IBD-I) patients were included in the 
UC category. All analyses were repeated for CD and UC patients separately. Descriptive statistics 
were performed to describe differences between the male and female sex groups. Categorical 
variables were compared by a Pearson χ2 test, and continuous variables by a Mann-Whitney-U test. 
Statistical analyses were performed with Stata Software V.13.1 (College Station, TX: Stata Corp LP) 
and SPSS version 21.0 (Armonk, NY: IBM Corp).
Ethical considerations
The Dutch IBD Biobank was carried out with the approval of both a Central Medical Ethics Committee 
(MEC) and approval of local MECs of all participating centers. The COIN study was carried out with 
the approval of the MEC of the University Medical Center, Utrecht.
Results
Patient population and male:female ratio
In the Dutch IBD Biobank, 2118 CD and 1269 UC patients were included. The male:female ratio was 
1:1.7 in CD and 1:1.1 in UC (Table 1). In the COIN study, 1139 CD patients and 1213 UC patients were 
included. The male:female ratio in this study was 1:1.6 in CD and 1:1.1 in UC (Table 1).
Demographic differences between female and male CD and UC patients
In the Dutch IBD Biobank, female CD patients were more often current smokers than male CD 
patients (43% versus 33%, P < 0.01). Male UC patients were more often previous smokers than 
female UC patients (51% versus 40%, P < 0.01) (Table 1). Comparable outcomes were observed in 
the COIN study (Table 1).
Differences in disease behaviour between female and male CD and UC patients
In the Dutch IBD Biobank, men were diagnosed with CD with early onset (younger than 16 years old) 
more frequently than women with CD (20% versus 12%, P < 0.01) (Table 2). Also, UC was diagnosed 
more often in men older than 40 years in comparison with women (and 33% versus 22%, P < 0.01, 
respectively). Ileal disease (Montreal L1) was encountered more frequently in male CD patients, 
while colonic disease (Montreal L2) was more common in female CD patients. Proctitis (Montreal 
E1) was more frequent in female than in male UC patients. In the COIN study, men with CD or UC 
were diagnosed at 40 years or older more often than women (29% versus 17% in CD; 42% versus 
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26% in UC, both P < 0.01) (Supplementary Table S1). No differences in the incidence of flares were 
observed between males and females in either cohort.
Table 1 Demographic differences between female and male IBD patients
Dutch IBD Biobank CD (n = 2118) UC (n = 1269)
Male Female P value Male Female P value 
Age at inclusion median years (IQR) 42 (31-56) 41 (31-52) 0.13 49 (36-60) 42 (33-53) < 0.01
Employed at baseline n (%) 415 (73) 557 (58) < 0.01 335 (79) 334 (73) < 0.05
Low education n (%) 366 (48) 753 (58) < 0.01 297 (51) 335 (52) 0.77
Smoking status n (%)
 Current 138 (33) 351 (43) < 0.01 62 (21) 68 (17) 0.26
 Never 283 (42) 471 (39) 0.23 235 (44) 321 (53) < 0.01
 Previously 259 (48) 392 (45) 0.39 241 (51) 212 (40) < 0.01
Family history of IBD† n (%) 231 (30) 382 (28) 0.47 154 (26) 165 (25) 0.78
COIN Study CD (n = 1139) UC (n = 1213)
Male Female P value Male Female P value 
Age at inclusion mean years (SD) 51 (14) 45 (13) < 0.01 54 (13) 46 (13) < 0.01
Employed at baseline n (%) 230 (72) 322 (64) 0.02 347 (80) 337 (81) 0.65
Low education n (%) 266 (60) 479 (69) < 0.01 371 (59) 363 (62) 0.36
Smoking status n (%) < 0.01 < 0.01
 Current 72 (16) 180 (26) < 0.01 57 (9) 78 (13) 0.02
 Never 233 (53) 331 (48) 0.10 334 (53) 339 (58) 0.12
 Previously 138 (31) 185 (27) 0.10 235 (38) 170 (29) < 0.01
Family history of IBD n (%) 98 (22) 149 (21) 0.95 116 (19) 126 (22) 0.44
†missing values were scored as non-present.
N: number; %: percentage of total; UC: ulcerative colitis; CD: Crohn’s disease; IBD: Inflammatory Bowel Disease; 
SD: standard deviation; IQR: interquartile range. 
Extraintestinal manifestations in female and male CD and UC patients
In the Dutch IBD Biobank, skin- and joint-manifestations were more common in female CD and UC 
patients than in male CD and UC patients (Table 3). Osteopenia and osteoporosis were diagnosed 
more often in male than in female CD patients (28% versus 21% in females, P < 0.01). After correcting 
for smoking behaviour, age at diagnosis, and disease duration, female sex was associated with EIMs 
with an adjusted odds ratio (OR) of 2.3 (95% CI: 1.9–2.8) in CD patients and an adjusted OR of 1.5 
(95% CI: 1.1–2.3) in UC patients (Supplementary Table S2). In the COIN study,19 a similar trend was 
observed, although it did not reach statistical significance (Supplementary Table S3). 
Surgery rates in female and male CD and UC patients
In the Dutch IBD Biobank, more male CD patients underwent small bowel and ileocaecal resection 
than female CD patients (16% versus 9%, and 40% versus 33%, respectively, both P < 0.01) (Table 
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4). No further differences in surgery rates between men and women (colon resection, ileostomy, 
colostomy, abscess/fistula surgery, and pouches) were observed. These observations were 
confirmed in the COIN study (Supplementary Table S4).
Table 2 Disease behaviour in female and male IBD patients in the Dutch IBD Biobank
CD (n = 2118) UC (n = 1269)
N (%) Male Female P value Male                           Female P value
Type of IBD < 0.01 < 0.01
 CD 773 (37) 1345 (63)
 UC 604 (48) 665 (52)
Disease duration at 
baseline median, years 
(IQR)
13 (6-22) 12 (6-21) 0.16 11 (5-20) 10 (5-18) 0.19
Montreal classification
 A1: diagnosis ≤ 16 years 153 (20) 166 (12) < 0.01 54 (9) 80 (12) 0.07
 A2: diagnosis 17-40 years 487 (63) 980 (73) < 0.01 348 (58) 437 (66) < 0.01
 A3: diagnosis > 40 years 133 (17) 199 (15) 0.14 202 (33) 148 (22) < 0.01
 L1: ileal diseasea 169 (28) 210 (20) < 0.01
 L2: colon diseasea 162 (26) 356 (33) < 0.01
 L3: ileocolon diseasea 280 (46) 500 (47) 0.67
 L4: upper GI disease† 76 (10) 101 (8) 0.06
 P: peri-anal disease† 221 (29) 342 (25) 0.11
 E1: proctitisb 26 (5) 59 (10) < 0.01
 E2: left-sided colitisb 179 (36) 197 (35) 0.86
 E3: extensive colitisb 299 (59) 307 (55) 0.11
Disease behaviour CD
 Fistulising† 102 (13) 236 (18) < 0.01
 Stricturing† 216 (28) 341 (25) 0.19
 Penetrating† 110 (14) 159 (12) 0.11
aThese percentages are calculated for 1677 CD patients (1066 female CD patients and 611 male CD patients);
bThese percentages are calculated for 1067 UC patients (563 female UC patients and 504 male UC patients);
†missing values were scored as non-present.
N: number; %: percentage of total; UC: ulcerative colitis; CD: Crohn’s disease; IBD: Inflammatory Bowel Disease; 
IQR: interquartile range.
Table 3 Extraintestinal manifestations in the Dutch IBD Biobank
CD (n = 2118) UC (n = 1269)
N (%) Male Female P value Male Female P value 
Skin manifestations† 47 (6) 203 (15) < 0.01 31 (5) 55 (8) 0.03
Arthropathy† 95 (12) 272 (20) < 0.01 55 (9) 95 (14 < 0.01
Arthritis† 27 (3) 119 (9) < 0.01 25 (4) 43 (6) 0.07
Ocular manifestations† 31 (4) 73 (5) 0.15 16 (3) 27 (4) 0.17
Osteopenia† 219 (28) 277 (21) < 0.01 93 (15) 87 (13) 0.24
†missing values were scored as non-present.
N: number; %: percentage of total; UC: ulcerative colitis; CD: Crohn’s disease.
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Table 4 Surgery rates in female and male IBD patients in the Dutch IBD Biobank
CD (n = 2118) UC (n = 1269)
N (%) Male Female P value Male Female P value 
Small bowel resection† 127 (16) 115 (9) < 0.01
Ileocaecal resection† 308 (40) 450 (33) < 0.01
Colon resection† 124 (16) 244 (18) 0.22 102 (17) 121 (18) 0.54
Strictureplasty† 44 (6) 45 (3) 0.01
Ileostomy/colostomy† 90 (12) 193 (14) 0.08 56 (9) 75 (11) 0.24
Surgery for abscesses or fistula† 160 (21) 307 (23) 0.26 13 (2) 14 (2) 0.95
Stoma† 90 (12) 180 (13) 0.25 63 (10) 69 (10) 0.98
Pouch† 13 (1.7) 25 (1.9) 0.77 52 (9) 65 (10) 0.47
Post operative stricture† 47 (6) 60 (4) 0.10
†missing values were scored as non-present.
N: number; %: percentage of total; UC: ulcerative colitis; CD: Crohn’s disease.
Table 5 Medication use and other healthcare use in female and male IBD patients in the COIN study
CD (n = 940)* UC (n = 1023)*
N (%) Male Female P value Male Female P value 
Anti-TNF 81 (22) 118 (21) 0.63 18 (3) 21 (4) 0.37
 Adalimumab 35 (10) 67 (12) 0.28 8 (2) 5 (1) 0.54
 Infliximab 47 (13) 51 (9) 0.06 10 (2) 16 (3) 0.13
Azathioprine 98 (27) 126 (22) 0.11 80 (15) 58 (12) 0.22
Mercaptoprine 25 (7) 46 (8) 0.47 35 (6) 27 (6) 0.59
Methotrexate 10 (3) 12 (2) 0.54 2 (0) 3 (1) 0.56
Budesonide 16 (4) 31 (5) 0.46 17 (3) 9 (2) 0.20
Prednisone 25 (7) 21 (4) 0.03 32 (6) 24 (5) 0.54
Sulfazalazine 6 (2) 8 (1) 0.79 3 (1) 6 (1) 0.23
Mesalazine 92 (25) 134 (23) 0.60 329 (61) 283 (59) 0.62
Use of diagnostics 89 (24) 123 (22) 0.36 92 (17) 73 (15) 0.45
Hospitalization due to IBD 19 (5) 17 (3) 0.09 14 (3) 18 (4) 0.28
Outpatient clinic visit due to IBD 171 (77) 281 (82) 0.11 234 (82) 197 (77) 0.12
N: number; %: percentage of total; UC: ulcerative colitis; CD: Crohn’s disease; *: At t = 3 months of follow-up
Medication use, healthcare consumption, and healthcare costs in female and male CD and 
UC patients
In the Dutch IBD Biobank, no differences regarding the use of IBD-specific medication (anti-TNFα 
compounds and immunomodulators) were observed between men and women (Supplementary 
Table S5).
In the COIN study, prednisone use was reported more frequently in male CD patients than in 
female CD patients (6.8% versus 3.7%, P = 0.03) (Table 5). No other differences regarding the use of 
IBD-specific medication, diagnostics, the number of hospitalizations, or the number of outpatient 
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clinic visits between men and women with CD or UC were observed. Quarterly healthcare costs 
did not differ between male and female CD and UC patients (Table 6).
Table 6 Mean healthcare costs in female and male patients in the COIN, calculated in euros for the year 2015, 
calculated over 3 months of follow-up
Mean € (95% CI) Male Female P value
Crohn’s disease (369 males and 572 females)
Total healthcare costs 1768 (1502 – 2075) 1520 (1298 – 1746) 0.19 
Medication costs 1205(1006– 1411) 1118 (953 – 1286) 0.52 
Hospitalization costs 370 (224 – 540) 198 (107 – 300) 0.08 
Surgery costs 3 (0 – 11) 14 (3 – 29) 0.27 
Diagnostics costs 48 (35 – 62) 46 (34 – 58) 0.89 
Outpatient clinic costs 125 (100 – 153) 127 (100 – 165) 0.94 
Ulcerative colitis (544 males and 480 females)
Total healthcare costs 538 (429 – 646) 608 (480 – 739) 0.45 
Medication costs 299 (234 – 365) 353 (269 – 447) 0.37 
Hospitalization costs 113 (50 – 183) 122 (50 – 195) 0.87 
Surgery costs 5 (0 – 12) 12 (0 – 24) 0.37 
Diagnostics costs 32 (24 – 42) 36 (25 – 47) 0.61 
Outpatient clinic costs 82 (71 – 95) 75 (62 – 88) 0.39
CI: confidence interval
Additional analysis: including all patients in the COIN cohort without removing duplicates
By analysing all variables described above in the COIN study without excluding patients who were 
also included in the Biobank study, no statistical differences were observed regarding the outcomes 
(data available on request).
Discussion
In this large nationwide multicenter study based on 2 IBD cohorts, we aimed to identify clinical 
relevant differences in disease characteristics and current clinical approach between female and 
male IBD patients. We observed that early onset CD (< 16 years old) was more prevalent in male 
patients. Ileal disease and small bowel surgery were more common in male than in female CD 
patients. Both female CD and UC patients suffered more often from EIMs than male patients. 
Prednisone use was higher in male CD patients compared to female CD patients. The use of other 
IBD-specific medication, outpatient clinic visits, diagnostic procedures, and hospitalizations did not 
differ between female and male IBD patients.
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Although correction for gender is frequently performed in the analysis of clinical parameters in 
IBD studies, results of previous studies usually did not correct for sex.20-22 Our finding in the Dutch 
IBD Biobank that male sex was associated with a CD diagnosis before the age of 16 years seems to 
have some base in previous literature.23 However, this observation was not confirmed in the COIN 
cohort. Differences in exposure to hormonal changes during pubertal development could underlie 
the sex-related differences of early onset CD,24 but environmental differences (such as diet and 
smoking behaviour) between males and females in puberty may also contribute.25
In the Dutch IBD Biobank, the ileum was more frequently affected in men with CD than in 
women. Prior data on this subject are scarce, with only 1 other study confirming our observation 
(i.e., ileitis terminal) in 33% of males versus 29% of females with CD.10 It is likely that the increased 
prevalence of ileal involvement translated into more small bowel and ileocaecal resections in men 
with CD. One could argue that higher resection rates reflect more severe disease behaviour in 
men. However, no other arguments for a more severe course in men were found in the Dutch IBD 
Biobank, since comparable numbers of male and female patients used anti-TNFα compounds and 
immunomodulators. Therefore, our data suggests that gender may be a potential risk factor for 
ileal disease involvement and subsequent ileal surgery. Prior reports regarding the role of gender 
in relation to (overall abdominal) surgery are conflicting.13,26
A multivariable analysis for EIMs in the COIN study has previously been published.19 In both 
cohorts, an association was found between female sex and EIMs in IBD patients.27-30 Smoking is 
strongly associated with EIMs,19 and one could hypothesize that the female association with EIMs is 
explained by the fact that women with IBD were more often smokers than men with IBD.31 However, 
multivariable analysis suggests that female sex is an independent risk factor for EIMs, in both CD 
and UC patients. Similarly, many rheumatic diseases, including rheumatoid arthritis (RA) are more 
common in women than in men.32 Sex hormones are thought to underlie this gender difference. 
In RA, disease activity is found to be correlated with prolactin plasma levels.33 Prolactin levels 
have been found to rise in women with RA post-partum, corresponding with a higher incidence 
of flares.34 Other suggested mechanisms include a lower level of serum androgens resulting in an 
increased production of interleukin-2 and suppression of the synthesis of autoantibodies.35,36 The 
same mechanisms might explain the higher incidence of EIMs in female IBD patients.
In the COIN study, prednisone was more often prescribed to male CD patients, but since the 
numbers were small, results need to be interpreted with caution. In regard to the use of other IBD-
specific medication, diagnostic procedures, outpatient clinic visits, hospitalizations, and associated 
costs, we found no gender differences in the COIN study. Only very few previous studies have 
reported on differences in IBD-related healthcare utilization in men and women. One study did not 
find a significant difference with respect to procedures (endoscopy, surgery, and blood transfusions) 
and the use of corticosteroids or biologic agents by comparing treatment between hospitalized 
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male and female adolescent CD patients.11 Another study found that female IBD patients were 
treated with immunosuppressive agents less frequently than male IBD patients.31 The authors 
hypothesize that this difference results from the tendency to prescribe less medication to women 
of child-bearing potential. However, a sub-analysis did not substantiate this assumption. Apart 
from more ileal and ileocolonic surgery in male CD patients in the Dutch IBD Biobank cohort, no 
differences in the management of male and female IBD patients were detected. Interestingly, in 
other immune-mediated diseases, female patients have been postulated to be less responsive to 
anti-TNFα therapy.37-39 The current study was not designed to assess response to therapy, therefore 
we cannot confirm nor refute this finding.
Strengths of this study include the large sample size (n > 5700) and the corroboration of 
two independent cohorts. Most of the observed differences between men and women were 
encountered in both cohorts or showed a similar trend, which supports the validity of both the 
separate cohorts and our conclusions of this current study. Moreover, the same results were 
obtained when repeating analyses for the complete COIN cohort, (i.e., including the duplicates 
from the IBD Biobank cohort). Specific strengths of the Dutch IBD Biobank are the standardized and 
concise method of phenotyping of the included patients. Strengths of the COIN study include the 
diversity of the case mix and the comprehensive and prospective way consumption of healthcare 
and associated healthcare costs were studied. Some differences between the 2 cohorts warrant 
comment. First, the Dutch IBD Biobank study exclusively recruited patients from university medical 
centers, whereas the COIN study included patients from both academic medical centers and general 
hospitals. Data collection in the Dutch IBD Biobank was predominantly conducted from medical 
records, while the data in the COIN study was self-reported. Self-reported information is generally 
less objective, and this could be considered a limitation. However, self-report is a validated method 
to study healthcare consumption and incurred healthcare costs in IBD patients.40 In addition, a non-
responder analysis showed no relevant statistical significant differences regarding demographic 
data (including gender) and disease course items between self-reported responders and non-
responders.17 Therefore, it was concluded that self-report reliably reflects consumption of health 
care in patients with IBD. With regard to disease characteristics, our findings were primarily based 
on the rigorous phenotyping from the Dutch IBD Biobank study.
In summary, our study revealed several sex differences between male and female IBD patients 
regarding age of onset, smoking behaviour, disease location, and EIMs. For example, both cohorts 
showed that smokers were most often female patients with CD. As smoking is a clinical parameter 
associated with severe disease course, clinicians should discuss this with every patient. This is 








Supplementary data are available at Inflammatory Bowel Diseases online.
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